SCHEMBL21541752

SCHEMBL21541752

C[C@@H]1CN(c2nnc3cnc4ccc(-c5ccc(N6CCC(N(C)C)CC6)cc5)nc4n23)C[C@H](C)O1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SYK P43405 2/20 0.36
▸ GAK O14976 3/20 0.35
▸ MET P08581 3/20 0.34
▸ PDE3B Q13370 1/20 0.34
▸ PDE3A Q14432 1/20 0.34
▸ MCHR1 Q99705 2/20 0.34
▸ PIK3CA P42336 1/20 0.34
▸ CDK1 P06493 1/20 0.34
▸ CDK4 P11802 1/20 0.34
▸ CCNB1 P14635 1/20 0.34
▸ CCND1 P24385 1/20 0.34
▸ CCND3 P30281 1/20 0.34
▸ CDK6 Q00534 1/20 0.34
▸ WEE1 P30291 1/20 0.32
▸ EGFR P00533 1/20 0.32
▸ ERBB3 P21860 1/20 0.32
▸ IRAK4 Q9NWZ3 1/20 0.32
▸ HTR1D P28221 2/20 0.32
▸ HTR3A P46098 2/20 0.32
▸ HTR6 P50406 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21541815 0.91 SYK (0.38) SYKMETPDE3BPDE3AMCHR1
SCHEMBL21541831 0.90 SYK (0.37) SYKMETPDE3BPDE3AMCHR1
SCHEMBL29559139 0.90 SYK (0.37) SYKMETPDE3BPDE3AMCHR1
SCHEMBL21541823 0.88 GAK (0.36) GAKMETPDE3BPDE3AWEE1
SCHEMBL21541761 0.88 KCNH2 (0.37) SYKMETPDE3BPDE3AMCHR1
SCHEMBL21541802 0.87 CSF1R (0.37) GAKMETPDE3BPDE3ACDK4
SCHEMBL21541857 0.86 CDK4 (0.35) GAKMETPDE3BPDE3ACDK4
SCHEMBL21541717 0.84 PRKDC (0.44) METPDE3BPDE3A
SCHEMBL21541912 0.81 PRKDC (0.47) PIK3CAEGFRERBB3
SCHEMBL30689454 0.81 PRKDC (0.47) PIK3CAEGFRERBB3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3567041-A9 SUBSTITUTED FUSED HETEROARYL COMPOUND SERVING AS A KINASE INHIBITOR, AND APPLICATIONS THEREOF Impact Therapeutics (Shanghai), Inc (CN) 2022-04-20 — — EP claimed
EP-3567041-A1 SUBSTITUTED FUSED HETEROARYL COMPOUND SERVING AS A KINASE INHIBITOR, AND APPLICATIONS THEREOF Impact Therapeutics, Inc (CN) 2019-11-13 — — EP claimed
EP-3567041-B1 SUBSTITUTED FUSED HETEROARYL COMPOUND SERVING AS A KINASE INHIBITOR, AND APPLICATIONS THEREOF IMPACT THERAPEUTICS SHANGHAI INC (CN) 2023-12-27 — — EP disclosed
EP-3567041-A9 SUBSTITUTED FUSED HETEROARYL COMPOUND SERVING AS A KINASE INHIBITOR, AND APPLICATIONS THEREOF Impact Therapeutics (Shanghai), Inc (CN) 2022-04-20 — — EP disclosed
US-10874670-B2 Substituted fused heteroaromatic compounds as kinase inhibitors and the use thereof IMPACT THERAPEUTICS, INC. (CN) 2020-12-29 — — US disclosed
EP-3567041-A1 SUBSTITUTED FUSED HETEROARYL COMPOUND SERVING AS A KINASE INHIBITOR, AND APPLICATIONS THEREOF Impact Therapeutics, Inc (CN) 2019-11-13 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10874670-B2 Substituted fused heteroaromatic compounds as kinase inhibitors and the use thereof CHEK1, CHEK2, CDK1 SYK 588/4885GAK 367/4885MET 1663/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback